EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tumor‐Targeted Radioiodinated Glyconanoparticles for Doxorubicin Delivery and Auger‐Chemotherapy in Triple‐Negative Breast Cancer

Shishu Kant Suman, Biji Balakrishnan, Madhava B Mallia, Archana Mukherjee iD

Small · 2025

DOI: 10.1002/smll.202502419 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2025. Verfasst von Shishu Kant Suman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, 400085, India. Hauptthemen laut MEDLINE: Doxorubicin, Triple Negative Breast Neoplasms, Nanoparticles, Drug Delivery Systems. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study focuses on developing a tumor‐responsive core‐shell glyconanoparticle formulation targeting galectin‐3 (Gal‐3) in triple‐negative breast cancer (TNBC) for Auger‐chemotherapy. The formulation utilizes citrus pectin dialdehyde (CPDA) to create nanoparticles capable of tumor‐responsive release of the drug Doxorubicin (Dox) for chemotherapy and incorporating the radionuclide, Iodine‐125 for Auger therapy. CPDA‐based core‐shell nanoparticles (CPDANP) are engineered for drug Dox release in the tumor microenvironment using boronate ester links between polymeric chains of CPDANP and imine linkages for conjugating Dox to CPDANP (CPDANP‐Dox). The nanoparticles are characterized for their size, effective charge, and core‐shell like structure by DLS and TEM and radiolabeled with 125 I. Gal‐3 specific targeting of CPDANP‐Dox and 125 I to the nucleus of tumor cells is confirmed by fluorescence microscopy and estimating radioactivity in the isolated nucleus of cells. In vitro and in vivo studies demonstrated that the combination therapy with [ 125 I] I‐CPDANP‐Dox exhibited enhanced cytotoxicity in TNBC cells. SPECT imaging and biodistribution studies showed rapid clearance of the formulations from the bloodstream, and tumor regression studies in 4T1 tumor‐bearing mice confirmed the therapeutic superiority of the combined treatment over individual therapies. This study highlights the potential of CPDANP as a dual‐targeting platform for efficient Auger‐chemo therapy in the treatment of TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinTriple Negative Breast NeoplasmsNanoparticlesDrug Delivery SystemsHumansAnimalsIodine RadioisotopesFemaleCell Line, TumorMiceTissue DistributionGalectin 3

Stichwörter der Autor:innen

auger radionuclide therapycore‐shell glyconanoparticlesdoxorubiciniodine‐125triple‐negative breast cancer (TNBC)

Substanzen

DoxorubicinIodine RadioisotopesIodine-125Galectin 3

Autor:innen und Institutionen

  • Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, 400085, India.
  • Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India.
  • Somaiya Center for Integrated Science Education and Research, Somaiya Vidyavihar University, Mumbai, 400077, India.

ORCID-Profile: Archana Mukherjee

Zitieren

APA

Suman, S. K., Balakrishnan, B., Mallia, M. B., & Mukherjee, A. (2025). Tumor‐Targeted Radioiodinated Glyconanoparticles for Doxorubicin Delivery and Auger‐Chemotherapy in Triple‐Negative Breast Cancer. Small. https://doi.org/10.1002/smll.202502419

Vancouver

Suman SK, Balakrishnan B, Mallia MB, Mukherjee A. Tumor‐Targeted Radioiodinated Glyconanoparticles for Doxorubicin Delivery and Auger‐Chemotherapy in Triple‐Negative Breast Cancer. Small. 2025. doi:10.1002/smll.202502419

BibTeX
@article{Suman2025,
  author = {Suman, Shishu Kant and Balakrishnan, Biji and Mallia, Madhava B and Mukherjee, Archana},
  title = {Tumor‐Targeted Radioiodinated Glyconanoparticles for Doxorubicin Delivery and Auger‐Chemotherapy in Triple‐Negative Breast Cancer},
  journal = {Small},
  year = {2025},
  doi = {10.1002/smll.202502419}
}
Kostenlos starten →